Trials / Terminated
TerminatedNCT03207256
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
An Open Label Extension Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination With Other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TGR-1202 | Oral Daily TGR-1202 |
| DRUG | TGR-1202 + Ublituximab | Oral Daily TGR-1202 + Ublituximab IV Administration |
Timeline
- Start date
- 2017-08-09
- Primary completion
- 2022-05-25
- Completion
- 2022-06-24
- First posted
- 2017-07-02
- Last updated
- 2022-07-21
Locations
17 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03207256. Inclusion in this directory is not an endorsement.